Medtronic beats Q4 estimates, shows highest revenue growth in 10 years, and trades at 24% discount to fair value.

Medtronic plc exceeded analyst expectations for revenue and non-GAAP EPS in Q4 2026, achieving its highest annual revenue growth in a decade. The company holds a strong A credit rating from S&P with a stable outlook. Despite this, Medtronic's stock is trading at a 24% discount to its estimated fair value, suggesting potential for a 32% total return by the end of fiscal year 2027 and 13% annual returns through 2032. This positions Medtronic as a promising dividend growth stock with potential for reaccelerated dividend growth in the next 1-2 years.